News
A standoff over Elevidys could have major consequences for Duchenne patients, gene therapy companies and the perception of ...
Part of a class of therapies that boost “orexin” proteins, the drug just scored positive results in a Phase 2 trial. Analysts ...
While Stelara is used in fewer indications than Humira, it commands a large market share in its therapeutic areas, most ...
A meeting held by the FDA Thursday spotlighted debate over black box warnings that have limited use of hormone treatment for ...
Overall venture funding, as well as “first financing” rounds, fell significantly in the second quarter, reversing 2025’s fast ...
The company had previously halted shipments to certain older patients following the deaths of two teenagers treated with the ...
Quarterly pharmaceutical sales surpassed $15 billion for the first time as strong performance from J&J's cancer medicines ...
Coartem Baby, which was cleared by health authorities in Switzerland, will fill an important gap in treatment. Novartis plans ...
The complaint argues Kennedy’s actions to remove the COVID vaccine from the CDC's immunization schedule for pregnant people ...
The cell therapy developer, which raised nearly $500 million in 2023 on the promise of its CAR-T work, has floundered since a ...
The drugmaker will provide, at no profit, doses to treat up to 2 million people in resource-limited countries. Meanwhile, Arvinas' John Houston is retiring from his role leading the biotech.
The death of a 51-year-old man in the study follows two other deaths of Duchenne patients treated with Sarepta’s marketed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results